Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Apetit Plc’s financial reporting and Annual General Meeting in 2021

Apetit Plc, Stock Exchange Release, 25 September 2020 at 09:00 a.m.Apetit Plc will publish its Financial Statements Review, Half Year Financial Review and two Business Reviews in 2021 as follows: February 19, 2021 at 8.30 a.m. - Financial Statements Review for 2020 May 7, 2021 at 8.30 a.m. - Business Review for January-March 2021 August 20, 2021 at 8.30 a.m. - Half Year Financial Review for January-June 2021 October 29, 2021 at 8.30 a.m. - Business Review for January-September 2021The Annual Report for 2020 including the Corporate Responsibility Report will be published during

Aktiebolaget Grundstenen 300029 announces a mandatory cash offer to the shareholders of Internationella Engelska Skolan i Sverige Holdings II AB (publ)

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT NOTICE” AT THE END OF THIS

Directorate Change

25 September 2020 07:00 BST  Non-Executive Board Appointment AstraZeneca PLC today announced that with effect from 1 October 2020, Dr Euan Ashley is appointed as a Non-Executive Director and a member of the Science Committee. Leif Johansson, Chairman of AstraZeneca, said: "We look forward to welcoming Euan to AstraZeneca and believe his scientific achievements and interests, which are well-aligned with our own BioPharmaceuticals R&D, together with his entrepreneurial experience on the US west coast will enable him to make a significant contribution to the Board's work." Euan

Qliro Group's Board of Directors proposes distribution of the shares in CDON AB to Qliro Group's shareholders

Press release, Stockholm, 25 September 2020 Qliro Group's Board of Directors will today convene an Extraordinary General Meeting on October 26, 2020 to resolve upon the distribution of all the shares in the wholly owned subsidiary CDON AB (“CDON”) to Qliro Group's shareholders. Provided that the Extraordinary General Meeting resolves upon the distribution, CDON's shares are expected to be admitted to trading on Nasdaq First North Growth Market. On Monday September 28, 2020, a previously convened Extraordinary General Meeting in Qliro Group will resolve upon a proposal to distribute the

Peab builds new main street in Lørenskog

Peab has been commissioned to build a new main street in Skårersletta in Lørenskog outside Oslo. The customer is Lørenskog Municipality and the contract is worth NOK 428 million.The new and modern main street will have broad sidewalks. There will be a raised bicycle lane on each side of the road, separated from driving lanes by the sidewalk curbs. The project is complex including a lot of heavy technology such as a district heating facility, street heating, waste suction and water, sewage and surface water solutions along with sheet metal and electricity work. Peab and the customer

Robust effects of VP01 in human idiopathic pulmonary fibrosis lung tissue

Gothenburg, September 25, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces effects of VP01 on idiopathic pulmonary fibrosis (IPF) patient tissue.Fresh human IPF lung tissue harvested from a patient during lung transplantation showed stable expression of the VP01 target, the angiotensin type 2 receptor (AT2R), and treatment with clinically relevant concentrations of VP01 caused a dose-dependent decrease of TGFb1, a key growth factor in fibrosis development. “It is reassuring that we can

SGL TransGroup completes subsequent bond issue

SGL TransGroup International A/S (the "Company" and the Company together with TransGroup Global Inc., and all their respective subsidiaries from time to time, the "Group") has successfully placed a subsequent bond issue in an amount of EUR 27 million under the framework of its outstanding bond loan with ISIN SE0013101219, following which the total outstanding amount will be EUR 250 million. The subsequent bond issue was priced at 98.50 per cent of par. The net proceeds from the subsequent bond issue will be used for general corporate purposes including acquisitions. The Company will

The City of Helsinki proposes a consortium of YIT and A-Kruunu to win the Kalasatama Nihti quality competition

YIT Corporation Press release, September 25, 2020, at 08:45 a.m.Lukki is the first residential block to be built in the Nihti local detailed plan area, located in a prominent place in the cityscape. The City of Helsinki proposes that four residential apartment building plots (known as the Lukki residential block) located in the Kalasatama Nihti local detailed plan area should be reserved for the consortium formed by YIT and A-Kruunu Oy. The Urban Environment Division will discuss the city’s proposal at their meeting on September 29, 2020. The Nihti local detailed plan is complete and

Swedencare AB (publ) completes a directed new share issue, raising approximately 340 million SEK to finance the acquisitions

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.   The board of directors of Swedencare AB (publ) (”Swedencare” or the ”Company”) has, in accordance with the Company’s press release earlier today, resolved on and carried out a

Elekta early out in securing MDR certificates for its linac portfolio

Compliance with regulations benefits hospitals and patients by securing market access and avoiding disruption of product deliveriesSTOCKHOLM, September 25, 2020 – Elekta (EKTA-B.ST) announced today it has received the EU Medical Device Regulation (EU MDR) certificate for its flagship linear accelerator (linac) portfolio. More than 4,000 Elekta linacs are currently clinical around the world, treating patients with a wide variety of cancers. The MDR certificate applies to the following products, including their components and accessories: · Versa HD™ · Elekta Synergy® · Elekta

New cooperation will enable fast charging in Northern Norway

Ishavskraft AS, one of Norway's largest power suppliers, is initiating a collaboration with Vattenfall and ABB. The companies will facilitate charging of electric cars in Northern Norway by installing and operating 24 new fast charging stations in the areas around Tromsö and Finnmark.Norway's goal is that 100 per cent of all new car sales are fossil free by 2025. In order to achieve this it is important to have charging infrastructure in place in all parts of the country. Seven power suppliers in the north have now chosen, together with Ishavskraft AS, to collaborate with Vattenfall and ABB

Kungsleden conducts strategic acquisition in Västerås City

Kungsleden is acquiring the Västerås Mimer 6 property from ABB. The property is strategically located at the very centre of Kungsleden’s Västerås City cluster. “The acquisition will enable us to expand our Västerås City community. We look forward to further strengthening our customer offering by creating modern and sustainable office spaces in the city centre,” says Mats Eriksson, Regional Manager Mälardalen. Kungsleden currently owns just over 150,000 sq.m. of commercial premises in central Västerås. The acquired property is strategically located at the very center of the

Getinge partnering with Universeum

Getinge partners up with Universeum – the largest science center in the Nordics. In this collaboration, the medtech company will support Universeum in their mission to strengthen skills supply and innovation, and to contribute to sustainable societal development with a particular focus on health.[Sportlov på Universeum] Photo: Universeum/Ellika Henrikson Universeum, national science center of Sweden and the largest of its kind in the Nordics, is a public arena for lifelong learning in which children and adults alike can explore the world through science, math and technology."We

BAKKAFROST: Share Savings Plan Transaction

As a part of the share savings plan for employees in 2020, the following primary insiders have purchased Bakkafrost shares: · Regin Jacobsen, CEO, purchased 26 shares. After the transaction, he holds 4,616,680 shares. · Odd Eliasen, Managing Director, purchased 21 shares. After the transaction, he holds 184,419 shares. · Høgni Dahl Jakobsen, CFO, purchased 16 shares. After the transaction, he holds 346 shares. · Annika Frederiksberg, Board Member, purchased 8 shares. After the transaction, she holds directly and indirectly 16,042 shares. The shares were purchased from P/F

Cyxone revises the development plan for Rabeximod

Cyxone AB (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that it has initiated a process to optimize the development plan for Rabeximod. This initiative is based on valuable input from the company’s new senior medical advisors, updated market intelligence and the opportunity to prolong market exclusivity through newly filed patent applications. In parallel, the company is preparing a phase 2 clinical study of Rabeximod in Covid-19 patients, with a potential initiation already in the fourth quarter of 2020.With a new CEO

Primary insider disclosure

The following primary insiders (or their related parties as described below) have, as part of the company's incentive program, committed to acquire shares in Ocean Yield ASA (the "Company" or "Ocean Yield"): · Lars Solbakken, CEO of Ocean Yield ASA, has through his wholly owned company Finmarine AS acquired 30,000 shares in Ocean Yield. Upon completion of such acquisition, Lars Solbakken will own, directly or indirectly, 1,670,880 shares in the Company. · Eirik Eide, CFO of Ocean Yield ASA, has through his wholly owned company Kleiver Invest AS acquired 30,000 shares in Ocean Yield.

Africa Energy to Present at Virtual Town Hall Meeting

VANCOUVER, BC, September 24, 2020 /CNW/ – Africa Energy Corp. (TSX Venture: AFE, Nasdaq First North Growth Market: AEC) (“Africa Energy” or the “Company”), an oil and gas company with exploration assets offshore South Africa and Namibia, will host a virtual town hall meeting on Wednesday, September 30, 2020, at 18:00 CEST (12:00 EDT). Mr. Garrett Soden, President and CEO, and Mr. Jan Maier, VP Exploration, will present an update on the company’s operations including the current exploration drilling program underway on Block 11B/12B offshore South Africa. All are welcome to join.

The first Brazilian Gripen has flown in Brazil

Today, September 24, the first Brazilian Gripen E, designated by Brazilian Air Force (FAB) as F-39 Gripen, concluded its first flight in Brazil. The aircraft flew from the airport in Navegantes to Embraer´s facility in Gavião Peixoto.The official presentation of the aircraft is scheduled to take place during the Aviator’s Day and the Brazilian Air Force Day ceremony in Brasilia, celebrated on the 23[rd] of October. “Gripen's arrival in Brazil and its first flight are major milestones in the Brazilian Gripen programme. We are proud of this journey alongside so many qualified and committed

Hansa Biopharm announces positive high-level data from investigator-initiated phase 2 trial with imlifidase to treat anti-GBM disease

Study concludes that imlifidase leads to rapid clearance of anti-GBM antibodies, with two-thirds of patients achieving dialysis independence six months after treatment Positive data demonstrates potential to increase renal survival in anti-GBM antibody disease and marks an important milestone for expansion of imlifidase outside transplantationLund, Sweden September 24, 2020. Hansa Biopharma (“Hansa”), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announces positive high-level data from an investigator-initiated phase 2 trial that evaluated safety,

Magnolia Bostad AB (publ) announces final tender results for certain senior unsecured bonds

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES AND

Look forward to the afterlife with Stellaris: Necroids Species Pack, Coming Soon

Stellaris and all expansions heavily discounted on Steam NowSTOCKHOLM - Sept 24, 2020 - Paradox Interactive, a publisher and developer of games that thrive on the dark side of the moon, has today announced Necroids - the next species pack for its grand strategy sci-fi game, Stellaris.   With the Necroids Species Pack, Stellaris gamers will learn that death is not the end, but rather the beginning of their intergalactic journey as new changes reincarnate playthroughs of Stellaris for long time players, as well as bringing new undeath to established playtypes. To live amongst the Necroids,

Design of Tellus Towers impacted by changes in plans for developing Telefonplan

The design of SSM’s Tellus Towers joint venture project at Stockholm’s Telefonplan will change as a result of a Stockholm City Planning Board decision regarding the development of central Telefonplan. As a result, 1,500 homes that were originally planned in the area will be reduced to about 1,000 and the two Tellus Towers skyscrapers will be replaced with a group of high-rise buildings. The intention is to create a greater variation of homes and a neighborhood that better blends in with Stockholm’s existing skyline. The decision is not expected to impact SSM’s results for Q3 or the full year

There are no items matching the current filter
There are no more items matching the current filter
Back to top